Abstract
Newly-emerged and vaccine-mismatched influenza A viruses (IAVs) result in a rapid global spread of the virus due to minimal antibody-mediated immunity. In that case, established CD8+ T-cells can reduce disease severity. However, as mutations occur sporadically within immunogenic IAV-derived T-cell peptides, understanding of T-cell receptor (TCRαβ) cross-reactivity towards IAV variants is needed for a vaccine design. Here, we investigate TCRαβ cross-strain recognition across IAV variants within two immunodominant human IAV-specific CD8+ T-cell epitopes, HLA-B*37:01-restricted NP338-346 (B37-NP338) and HLA-A*01:01-restricted NP44-52 (A1-NP44). We find high abundance of cross-reactive TCRαβ clonotypes recognizing distinct IAV variants. Structures of the wild-type and variant peptides revealed preserved conformation of the bound peptides. Structures of a cross-reactive TCR-HLA-B37-NP338 complex suggest that the conserved conformation of the variants underpins TCR cross-reactivity. Overall, cross-reactive CD8+ T-cell responses, underpinned by conserved epitope structure, facilitates recognition of distinct IAV variants, thus CD8+ T-cell-targeted vaccines could provide protection across different IAV strains.
Highlights
Newly-emerged and vaccine-mismatched influenza A viruses (IAVs) result in a rapid global spread of the virus due to minimal antibody-mediated immunity
CD8+ T cells primed with seasonal circulating IAV strains can cross-react with pandemic H1N1 or variant seasonal peptides[20,21,22] or virulent H7N9 and H5N1 avian IAV-derived peptides[23,24,25,26]
NP338 was previously reported to be restricted by HLA-B*44:0341
Summary
Newly-emerged and vaccine-mismatched influenza A viruses (IAVs) result in a rapid global spread of the virus due to minimal antibody-mediated immunity. Cross-reactive CD8+ T-cell responses, underpinned by conserved epitope structure, facilitates recognition of distinct IAV variants, CD8+ T-celltargeted vaccines could provide protection across different IAV strains. CD8+ T cells primed with seasonal circulating IAV strains can cross-react with pandemic H1N1 (pH1N1) or variant seasonal peptides[20,21,22] or virulent H7N9 and H5N1 avian IAV-derived peptides[23,24,25,26] Together, these data suggest that an IAV-specific CD8+ T cell-mediated vaccine can provide broad cross-reactive immunity across distinct influenza A strains and subtypes for both conserved and variable CD8+ T cell epitopes. In case of highly mutating influenza viruses, such cross-reactive CD8+ T cells are highly desirable as they elicit immune responses towards multiple viral strains and provide cross-strain protection
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.